Tue, 23 Feb 2010 09:51:34 -0500 NUVIS Group http://www.peerviewpress.com Podcast Maker v1.3 - http://www.lemonzdream.com/podcastmaker PeerView Press is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. Thought leader perspectives on current clinical advances in medicine. PeerView Press is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. 2010 PeerView Press, 42 Brook Street, Mayfair, London, W1K 5DB webmaster@peerviewpress.com http://media.peerviewpress.com/000136/podcast/nuvis/xml/vidOncology_intl_144.jpg http://www.peerviewpress.com 144 144 Science & Medicine CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, Oncology no NUVIS Group Advances in the Treatment of Breast Cancer: Results From the BIG 1-98 Trial Go online to www.peerviewpress.com/h/j3 to view the entire programme with slides. Advances in the Treatment of Breast Cancer: Results From the BIG 1-98 Trial http://media.peerviewpress.com/000136/podcast/nuvis/m4v/ANINT05996j3.m4v Thu, 29 Apr 2010 10:20:11 -0500 Science & Medicine no 00:19:49 BIG 1-98, letrozole, tamoxifen, sequential, cross-over, censoring, ITT, intention-to-treat, IPCW, inverse proportion censoring weighted, bias, STA, sequential therapy analysis, monotherapy, unblinding, adjuvant, early breast cancer, endocrine responsive NUVIS Group Focusing on the Factors That Affect Outcomes in Patients With GIST Go online to www.peerviewpress.com/h/s168 to view the entire programme with slides. Focusing on the Factors That Affect Outcomes in Patients With GIST http://media.peerviewpress.com/000136/podcast/nuvis/m4v/ANINT06434s168.m4v Fri, 19 Mar 2010 10:20:11 -0500 Science & Medicine no 00:16:43 GIST, gastrointestinal stromal tumour, nomogram, Miettinen, AFIP, Fletcher, staging system, risk of recurrence, ACOSOG Z9001, dose escalation, Cmin, plasma trough, gastrectomy, exon 9, exon 11, KIT mutation, metaGIST, survival, TTP, PFS, RFS, ADAGIO, adherence, nonadherence NUVIS Group Clinical Benefits of Anti-Angiogenic Agents in First-Line NSCLC: Benchtop to Clinical Practice Go online to www.peerviewpress.com/h/r103 to view the entire programme with slides. Clinical Benefits of Anti-Angiogenic Agents in First-Line NSCLC: Benchtop to Clinical Practice http://media.peerviewpress.com/000136/podcast/nuvis/m4v/ENUVI06449r103_QAApp_290110.m4v Fri, 22 Jan 2010 10:20:14 -0500 Science & Medicine no 00:20:25 non-small-cell lung cancer oncology anti-angiogenic angiogensis biologic targeted bevacizumab survival safety NUVIS Group The Impact of FGFR Inhibition on Breast Cancer and Other Solid Tumours Go online to www.peerviewpress.com/h/r98 to view the entire programme with slides. The Impact of FGFR Inhibition on Breast Cancer and Other Solid Tumours http://media.peerviewpress.com/000136/podcast/nuvis/m4v/ANINT06008r98.m4v Thu, 24 Dec 2009 11:46:22 -0500 Science & Medicine no 00:09:41 fibroblast growth factor receptor inhibitor, FGFR, ligand, breast cancer, solid tumour, receptor tyrosine kinase, RTK, HER2, signalling, prostate, bladder, multiple myeloma, lymphoma, NSCLC, ovarian, hepatocellular, colorectal, TKI258 NUVIS Group Case-Based Approach to Emerging 2009 GIST Management Go online to www.peerviewpress.com/h/p14 to view the entire programme with slides. Case-Based Approach to Emerging 2009 GIST Management http://media.peerviewpress.com/000136/podcast/nuvis/m4v/ENUVI05901p14.m4v Fri, 16 Oct 2009 14:59:45 -0400 Science & Medicine no 00:41:44 GIST, gastrointestinal stromal tumour, adjuvant, imatinib, sunitinib, size, location, mitotic rate, NCCN, ESMO, survival, ACOSOG NUVIS Group Improving Second-Line Treatment in Advanced Ovarian Cancer Go online to www.peerviewpress.com/h/s151 to view the entire programme with slides. Improving Second-Line Treatment in Advanced Ovarian Cancer http://media.peerviewpress.com/000136/podcast/nuvis/m4v/ANINT06277s151.m4v Fri, 18 Sep 2009 11:53:12 -0400 Science & Medicine no 00:18:42 Ovarian cancer, advanced, recurring, chemotherapy, platinum-based, combination, carboplatin, PLD, pegylated, liposomal, doxorubicin, paclitaxel, CALYPSO NUVIS Group GIST: Evolving Treatment Algorithms to Optimise Care Go online to www.peerviewpress.com/h/s137 to view the entire programme with slides. GIST: Evolving Treatment Algorithms to Optimise Care http://media.peerviewpress.com/000136/podcast/nuvis/m4v/NI05786FCs137.m4v Mon, 10 Aug 2009 10:14:19 -0400 Science & Medicine no 00:16:41 GIST, gastrointestinal stromal tumour, imatinib, adjuvant, neoadjuvant, advanced, metastatic, locally advanced, mitotic rate, Z9001, ESMO, NCCN, time to secondary resistance, BFR14 NUVIS Group New Developments in NSCLC: Extending the Benefit of First-Line Therapy Go online to www.peerviewpress.com/h/r463 to view the entire programme with slides. New Developments in NSCLC: Extending the Benefit of First-Line Therapy http://media.peerviewpress.com/000136/podcast/nuvis/m4v/NE05271FCr463.m4v Thu, 23 Jul 2009 10:56:38 -0400 Science & Medicine no 00:23:20 lung cancer, non small cell lung cancer, bevacizumab, erlotinib, cetuximab, gefitinib, pemetrexed, maintenance therapy, EGFR, K-RAS or KRAS or kras NUVIS Group Adjuvant Therapy for GIST: Learning From the Present to Change the Future of Treatment Go online to www.peerviewpress.com/h/s552 to view the entire programme with slides. Adjuvant Therapy for GIST: Learning From the Present to Change the Future of Treatment http://media.peerviewpress.com/000136/podcast/nuvis/m4v/NI04797FCs552.m4v Tue, 28 Apr 2009 11:59:26 -0400 Science & Medicine no 00:18:10 localised GIST, gastrointestinal stromal tumours, ACOSOG Z9001, imatinib, sunitinib, adjuvant, neoadjuvant, ESMO, NCCN, exon 11 mutation, reGISTry, SEER, surgical resection NUVIS Group Guidelines on the Prevention and Treatment of Cancer-Associated Thrombosis Go online to www.peerviewpress.com/h/r449 to view the entire programme with slides. Guidelines on the Prevention and Treatment of Cancer-Associated Thrombosis http://media.peerviewpress.com/000136/podcast/nuvis/m4v/NI05275FCr449.m4v Fri, 13 Mar 2009 13:37:14 -0400 Science & Medicine no 00:50:37 VTE, venous thromboembolism, ASCO, ESMO, cancer, recurrent thromboembolism, thromboprophylaxis, surgery, pulmonary embolism, CANTHANOX, CLOT NUVIS Group Therapeutic Decisions in Second-Line NSCLC Go online to www.peerviewpress.com/h/p154 to view the entire programme with slides. Therapeutic Decisions in Second-Line NSCLC http://media.peerviewpress.com/000136/podcast/nuvis/m4v/NE05249FCp154.m4v Thu, 12 Mar 2009 10:33:37 -0400 Science & Medicine no 00:15:49 Non–small-cell lung cancer, Tarceva, erlotinib, EGFR TKI, tyrosine kinase inhibitor, docetaxel, pemetrexed, squamous, neutropenia, adenocarcinoma, platinum failure, rash NUVIS Group Using Targeted Therapy to Improve Outcomes in Multiple Tumours Go online to www.peerviewpress.com/h/s528 to view the entire programme with slides. Using Targeted Therapy to Improve Outcomes in Multiple Tumours http://media.peerviewpress.com/000136/podcast/nuvis/m4v/NI04932FCs528_QAApp_100309.m4v Fri, 20 Feb 2009 14:03:25 -0500 Science & Medicine no 00:27:21 mammalian target of rapamycin, mTOR inhibitors, neuroendocrine tumours, renal cell carcinoma, RCC, NET, RECORD-1, RAD001, everolimus, temsirolimus, deforolimus NUVIS Group Guidelines on the Prevention and Treatment of Cancer-Associated Thrombosis Go online to www.peerviewpress.com/h/s526 to view the entire programme with slides. Guidelines on the Prevention and Treatment of Cancer-Associated Thrombosis http://podcast.peerviewpress.com/OncologyVideoNonCME_Int/NE05096FCs526.m4v http://podcast.peerviewpress.com/OncologyVideoNonCME_Int/NE05096FCs526.m4v Mon, 02 Feb 2009 10:42:33 -0500 Science & Medicine no 00:39:14 VTE, venous thromboembolism, ASCO, ESMO, cancer, recurrent thromboembolism, thromboprophylaxis, surgery, pulmonary embolism, CANTHANOX, CLOT NUVIS Group Case-Based Approach to Emerging 2008 GIST Management Go online to www.peerviewpress.com/h/p137 to view the entire programme with slides. Case-Based Approach to Emerging 2008 GIST Management http://media.peerviewpress.com/000136/podcast/nuvis/m4v/NI04141FCp137.m4v Tue, 09 Dec 2008 11:26:55 -0500 Science & Medicine no 00:39:53 GIST, adjuvant, imatinib, sunitinib, size, location, mitotic rate, NCCN, ESM NUVIS Group Evidence-Based Decisions in the Management of Advanced Prostate Cancer Go online to www.peerviewpress.com/h/r419 to view the entire programme with slides. Evidence-Based Decisions in the Management of Advanced Prostate Cancer http://media.peerviewpress.com/000136/podcast/nuvis/m4v/NE04518FCr419_QAAppr_201108.m4v Thu, 23 Oct 2008 11:26:33 -0400 Science & Medicine no 00:25:51 HRPC, chemotherapy, urologists, oncologists, prostate cancer, PSA, seniors, metastasis, advanced prostate cancer, systemic therapy, minimal pain HRPC, elderly NUVIS Group Update on GIST Treatment Strategies: What the Latest Evidence Indicates Go online to www.peerviewpress.com/h/s478 to view the entire programme with slides. Update on GIST Treatment Strategies: What the Latest Evidence Indicates http://media.peerviewpress.com/000136/podcast/nuvis/m4v/NI04796FCs478.m4v Tue, 02 Sep 2008 11:27:18 -0400 Science & Medicine no 00:18:54 GIST, gastrointestinal stromal tumours, adjuvant, B2222, ACOSOG Z9000, Z9001, plasma level, trough, imatinib, mutation status, KIT, PDGFR, platelet-derived growth factor receptor, exon 11, exon 9, Cmin, quartile, ESMO, European Society of Medical Oncology NUVIS Group Antitumour Activity of Bisphosphonates: Myth or Reality? Go online to www.peerviewpress.com/h/r406 to view the entire programme with slides. Antitumour Activity of Bisphosphonates: Myth or Reality? http://media.peerviewpress.com/000136/podcast/nuvis/m4v/NI04887FCr406.m4v Thu, 05 Jun 2008 10:58:06 -0400 Science & Medicine no 00:08:29 zoledronic acid, bisphosphonates, antitumour activity, osteoblasts, osteoclasts, FPP synthase, tumour cell growth NUVIS Group Pathways of Innovation in Oncology: Improving Patient Outcomes in the Treatment of Renal Cell Carcinoma Go online to www.peerviewpress.com/h/r376 to view the entire programme with slides. Pathways of Innovation in Oncology: Improving Patient Outcomes in the Treatment of Renal Cell Carcinoma http://media.peerviewpress.com/000136/podcast/nuvis/m4v/NI04660FCr376.m4v Wed, 21 May 2008 14:28:25 -0400 Science & Medicine no 00:17:40 PeerView Press, inSession, inReview, Oncology NUVIS Group Exploring the Anthracycline Controversy in Breast Cancer: What Does the Evidence Tell Us? Go online to www.peerviewpress.com/h/s466 to view the entire programme with slides. Exploring the Anthracycline Controversy in Breast Cancer: What Does the Evidence Tell Us? http://media.peerviewpress.com/000136/podcast/nuvis/m4v/NE04167FCs466.m4v Thu, 08 May 2008 14:28:34 -0400 Science & Medicine no 00:34:48 ]anthracycline, nonanthracycline, taxane, docetaxel, HER2, hormone receptor, dose-dense, gene signature, NSABP B-30, NSABP B-38, 06090, MINDACT, amplification NUVIS Group Recent Data on First-Line Treatment Options for NSCLC: Implications for Clinical Practice Go online to www.peerviewpress.com/h/r397 to view the entire programme with slides. Recent Data on First-Line Treatment Options for NSCLC: Implications for Clinical Practice http://media.peerviewpress.com/000136/podcast/nuvis/m4v/NE04164FCr397.m4v Fri, 25 Apr 2008 10:07:01 -0400 Science & Medicine no 00:31:47 docetaxel, bevacizumab, cetuximab, paclitaxel, vinorelbine, vinca alkaloid, non-small-cell lung cancer, lung cancer, NSCLC NUVIS Group Update on Second-Line Treatment Options in Advanced NSCLC: Cytotoxic and Targeted Therapies Go online to www.peerviewpress.com/h/r385 to view the entire programme with slides. Update on Second-Line Treatment Options in Advanced NSCLC: Cytotoxic and Targeted Therapies http://media.peerviewpress.com/000136/podcast/nuvis/m4v/NE04571FCr385.m4v Fri, 22 Feb 2008 17:06:28 -0500 Science & Medicine no yes 00:26:03 NSCLC, non-small-cell lung cancer, Tarceva, erlotinib, gefitinib, EGFR TKI, tyrosine kinase inhibitor NUVIS Group Biologic Agents Targeting Multiple Receptors for the Treatment of Non-Small-Cell Lung Cancer (NSCLC) Go online to www.peerviewpress.com/h/r342 to view the entire programme with slides. Biologic Agents Targeting Multiple Receptors for the Treatment of Non-Small-Cell Lung Cancer (NSCLC) http://media.peerviewpress.com/000136/podcast/nuvis/m4v/NE03840FC_r342_video_podcast_QAApp_141207.m4v Wed, 12 Dec 2007 15:31:38 -0500 Science & Medicine no 00:16:06 Vandetanib, epidermal growth factor receptor, vascular endothelial growth factor, sorafenib, sunitinib, vatalanib NUVIS Group Treatment of Solid Tumours: Update From ECCO Go online to www.peerviewpress.com/h/s456 to view the entire programme with slides. Treatment of Solid Tumours: Update From ECCO http://media.peerviewpress.com/000136/podcast/nuvis/m4v/NI04226FC456.m4v Wed, 21 Nov 2007 09:42:37 -0500 Science & Medicine no 00:36:53 Metastatic breast cancer, breast cancer, lung cancer, NSCLC, taxane, paclitaxel, nab-paclitaxel, protein-bound paclitaxel, albumin-bound paclitaxel, ECCO, peripheral neuropathy, Cremophor, adjuvant chemotherapy, neoadjuvant chemotherapy